WO2002069711A1 - Therapie genique pour tissus neurologiques - Google Patents

Therapie genique pour tissus neurologiques Download PDF

Info

Publication number
WO2002069711A1
WO2002069711A1 PCT/US2002/005886 US0205886W WO02069711A1 WO 2002069711 A1 WO2002069711 A1 WO 2002069711A1 US 0205886 W US0205886 W US 0205886W WO 02069711 A1 WO02069711 A1 WO 02069711A1
Authority
WO
WIPO (PCT)
Prior art keywords
cerebrospinal
flow
growth factor
gene therapy
fluid
Prior art date
Application number
PCT/US2002/005886
Other languages
English (en)
Inventor
David P. Hesson
Glenn D. Frazer
Bruce Shook
Original Assignee
Neuron Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Therapeutics, Inc. filed Critical Neuron Therapeutics, Inc.
Priority to EP02713697A priority Critical patent/EP1370138A4/fr
Publication of WO2002069711A1 publication Critical patent/WO2002069711A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un procédé d'application, sur un tissu neurologique, d'une composition de transformation ou d'une cellule transformée. Ce procédé consiste : (a) à injecter un liquide de perfusion cérébro-spinal physiologiquement acceptable dans un premier cathéter dans la voie cérébro-spinale, ce liquide perfusion cérébro-spinal possédant une quantité efficace en thérapie génique d'un agent de thérapie génique ou de cellules transformées ; (b) à prélever du liquide au moyen d'un deuxième cathéter et à l'injecter dans la voie cérébro-spinale afin de créer un flux et une voie de flux entre les premier et deuxième cathéters ; et (c) à conserver le flux pendant une durée suffisante pour perfuser au moins un volume de liquide céphalo-rachidien.
PCT/US2002/005886 2001-03-02 2002-02-28 Therapie genique pour tissus neurologiques WO2002069711A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP02713697A EP1370138A4 (fr) 2001-03-02 2002-02-28 Therapie genique pour tissus neurologiques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79877501A 2001-03-02 2001-03-02
US09/798,775 2001-03-02

Publications (1)

Publication Number Publication Date
WO2002069711A1 true WO2002069711A1 (fr) 2002-09-12

Family

ID=25174236

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/005886 WO2002069711A1 (fr) 2001-03-02 2002-02-28 Therapie genique pour tissus neurologiques

Country Status (2)

Country Link
EP (1) EP1370138A4 (fr)
WO (1) WO2002069711A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115880A2 (fr) * 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Utilisation de leptine pour le traitement ou la prévention de la maladie de parkinson

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569180A (en) * 1991-02-14 1996-10-29 Wayne State University Method for delivering a gas-supersaturated fluid to a gas-depleted site and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002005870A2 (fr) * 2000-07-19 2002-01-24 Neuron Therapeutics, Inc. Kits et compositions pour la realisation d'injections intracraniennes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569180A (en) * 1991-02-14 1996-10-29 Wayne State University Method for delivering a gas-supersaturated fluid to a gas-depleted site and use thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ABBOTT ET AL.: "Transporting therapeutics across the blood-brain barrier", MOLECULAR MEDICINE TODAY, vol. 2, March 1996 (1996-03-01), pages 106 - 113, XP002952585 *
BRAY G.M.: "Neural transplantation", CURRENT OPINION IN NEUROLOGY AND NEUROSURGERY, vol. 3, 1990, pages 926 - 933, XP002952586 *
HORNER ET AL.: "Regenerating the damaged central nervous system", NATURE, vol. 407, 26 October 2000 (2000-10-26), pages 963 - 969, XP002952587 *
LINDVALL O.: "Engineering neurons for Parkinson's disease", NATURE BIOTECHNOLOGY, vol. 17, July 1999 (1999-07-01), pages 635 - 636, XP002906547 *
PRICE ET AL.: "Neural stem cells", CURRENT OPINION IN NEUROBIOLOGY, vol. 11, October 2001 (2001-10-01), pages 564 - 567, XP002952588 *
See also references of EP1370138A4 *
WAGNER ET AL.: "Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes", NATURE BIOTECHNOLOGY, vol. 17, July 1999 (1999-07-01), pages 653 - 659, XP002154887 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008115880A2 (fr) * 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Utilisation de leptine pour le traitement ou la prévention de la maladie de parkinson
WO2008115880A3 (fr) * 2007-03-21 2009-09-11 The Board Of Regents Of The University Of Texas System Utilisation de leptine pour le traitement ou la prévention de la maladie de parkinson

Also Published As

Publication number Publication date
EP1370138A4 (fr) 2004-08-18
EP1370138A1 (fr) 2003-12-17

Similar Documents

Publication Publication Date Title
ES2960939T3 (es) Agentes crioprotectores para formulaciones particuladas
Stewart et al. Gene transfer in vivo with DNA–liposome complexes: safety and acute toxicity in mice
Parker et al. Nonviral gene delivery: techniques and implications for molecular medicine
Ledley Nonviral gene therapy: the promise of genes as pharmaceutical products
ES2265569T3 (es) Composicion farmaceutica que mejora la transferencia de genes in vivo.
Dass Vehicles for oligonucleotide delivery to tumours
JP4275728B2 (ja) 核酸を含有する組成物、その製造および使用
US20050265957A1 (en) Polymerized formamides for use in delivery of compounds to cells
US20070293449A1 (en) Compositions and methods for delivery of double-stranded rna
JPH09508100A (ja) 核酸を含む組成物、調製および使用
US6989374B1 (en) Gene therapy for cardiomyopathy
Kaur et al. Modified mRNA as a Therapeutic Tool for the Heart
Chen et al. Ultrasound‐and liposome microbubble‐mediated targeted gene transfer to cardiomyocytes in vivo accompanied by polyethylenimine
Ahn et al. Where should siRNAs go: applicable organs for siRNA drugs
Zahir-Jouzdani et al. siRNA delivery for treatment of degenerative diseases, new hopes and challenges
WO2004072248A2 (fr) Processus d'administration de sirna a un tissu de muscle cardiaque
Stanton Current status of messenger RNA delivery systems
Li et al. Biosafety assessment of delivery systems for clinical nucleic acid therapeutics
Wang et al. Combination of electroporation and DNA/dendrimer complexes enhances gene transfer into murine cardiac transplants
Mohammad Key considerations in formulation development for gene therapy products
JP3877148B2 (ja) 糖尿病性虚血性疾患遺伝子治療
Wang et al. Gene therapy strategies for rare monogenic disorders with nuclear or mitochondrial gene mutations
US20020193335A1 (en) Gene therapy for neurological tissues
EP1370138A1 (fr) Therapie genique pour tissus neurologiques
Peddi et al. Intrauterine fetal gene therapy: is that the future and is that future now?

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002713697

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002713697

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002713697

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP